BHVN Biohaven Pharmaceutical Holding Company Ltd.

44.63
+1.51  (+4%)
Previous Close 43.12
Open 43.39
Price To Book 12.47
Market Cap 2,327,646,230
Shares 52,154,296
Volume 388,002
Short Ratio 7.81
Av. Daily Volume 685,094
Stock charts supplied by TradingView

NewsSee all news

  1. Biohaven's Verdiperstat, An Oral Myeloperoxidase Inhibitor, Selected For Platform Trial Collaboration At Massachusetts General Hospital's Healey & AMG Center For Amyotrophic Lateral Sclerosis (ALS)

    NEW HAVEN, Conn., Sept. 18, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) ("Biohaven" or the "Company"), a clinical stage biopharmaceutical company with a portfolio of

  2. Biohaven Advances NOJECTION™ Migraine Platform With Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant, The First Intranasally Administered CGRP Receptor Antagonist In Development For The Acute Treatment Of Migraine

    NEW HAVEN, Conn., Sept. 10, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), a biotechnology company focused on advancing innovative therapies for neurological and neuropsychiatric diseases,

  3. Biohaven Presents Data Demonstrating Reduction In Migraine-Related Disability And Improvement In Patient Reported Outcomes After Oral Treatment With Rimegepant At The International Headache Conference Late Breaking Session

    NEW HAVEN, Conn., Sept. 9, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) announced today that it presented expanded data and post-hoc analyses from its long term clinical study

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2/3 top-line data due 1Q 2020.
TRORILUZOLE
Obsessive compulsive disorder (OCD)
CRL issued July 19, 2019.
Nurtec (riluzole) (BHV-0223)
Amyotrophic lateral sclerosis (ALS)
Phase 3 top-line data due 4Q 2019.
Rimegepant
Migraine - preventative
NDA filing submitted 2Q 2019.
Rimegepant
Acute treatment of migraine
Phase 2 enrolment to be completed 4Q 2019. Futility analysis also due 4Q 2019.
TRORILUZOLE
Alzheimer’s disease
Phase 2/3 top-line data due 4Q 2019.
TRORILUZOLE
Generalized anxiety disorder (GAD)
Phase 3 commencement of enrolment announced July 31, 2019.
Verdiperstat
Multiple system atrophy (MSA)
Phase 2/3 completion of enrolment announced September 10, 2019 with top-line data due 4Q 2019.
Vazegepant
Acute treatment of migraine
Phase 3 enrolment to be completed 1Q 2020.
TRORILUZOLE
Spinocerebellar Ataxia (SCA)
Phase 2 commencement of enrolment announced July 1, 2019.
Rimegepant
Refractory trigeminal neuralgia

Latest News

  1. Biohaven's Verdiperstat, An Oral Myeloperoxidase Inhibitor, Selected For Platform Trial Collaboration At Massachusetts General Hospital's Healey & AMG Center For Amyotrophic Lateral Sclerosis (ALS)

    NEW HAVEN, Conn., Sept. 18, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) ("Biohaven" or the "Company"), a clinical stage biopharmaceutical company with a portfolio of

  2. Biohaven Advances NOJECTION™ Migraine Platform With Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant, The First Intranasally Administered CGRP Receptor Antagonist In Development For The Acute Treatment Of Migraine

    NEW HAVEN, Conn., Sept. 10, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), a biotechnology company focused on advancing innovative therapies for neurological and neuropsychiatric diseases,

  3. Biohaven Presents Data Demonstrating Reduction In Migraine-Related Disability And Improvement In Patient Reported Outcomes After Oral Treatment With Rimegepant At The International Headache Conference Late Breaking Session

    NEW HAVEN, Conn., Sept. 9, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) announced today that it presented expanded data and post-hoc analyses from its long term clinical study